DBV Technologies SA - Company Profile (NASDAQ:DBVT)

Analyst Ratings

Consensus Ratings for DBV Technologies SA - (NASDAQ:DBVT) (?)
Ratings Breakdown: 7 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $51.57 (49.05% upside)

Analysts' Ratings History for DBV Technologies SA - (NASDAQ:DBVT)
Show:
DateFirmActionRatingPrice TargetActions
6/8/2016Jefferies GroupReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/16/2016Citigroup Inc.Lower Price TargetBuy$48.00 -> $43.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/8/2016Leerink SwannReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/7/2016HC WainwrightReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/3/2015Barclays PLCInitiated CoveragePositive -> Overweight$58.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/23/2015Bank of America Corp.Initiated CoverageBuy$48.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/15/2015Morgan StanleyInitiated CoverageOverweight$59.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/30/2014 forward)

Earnings

Earnings History for DBV Technologies SA - (NASDAQ:DBVT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
3/26/2015($0.44)($0.79)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for DBV Technologies SA - (NASDAQ:DBVT)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q4 20161($0.87)($0.87)($0.87)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for DBV Technologies SA - (NASDAQ:DBVT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for DBV Technologies SA - (NASDAQ:DBVT)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for DBV Technologies SA - (NASDAQ:DBVT)
DateHeadline
07/28/16 04:08 AMFirst Half of 2016 Condensed Consolidated Financial Statements - [at noodls] - FIRST HALF OF 2016 CONDENSED CONSOLIDATED FINANCIAL STATEMENTS The epicutaneous immunotherapy company CONTENT I - FIRST HALF 2016 CONDENSED CONSOLIDATED FINANCIAL STATEMENTS II - MANAGEMENT DISCUSSION ...
07/28/16 12:38 AMDBV Technologies Reports Interim Financial Results for the First Half of 2016 - [at noodls] - Press Release Montrouge, France, July 28, 2016 DBV Technologies Reports Interim Financial Results for the First Half of 2016 DBV Technologies, (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: ...
07/26/16 09:43 AMDBV Technologies SA :DBVT-US: Earnings Analysis: For the six months ended December 31, 2015 : July 26, 2016 -
07/16/16 04:15 AMStrong Sell Calls For DBV Technologies S.A. (NASDAQ:DBVT) At 0 - Investor Newswire
07/14/16 06:02 AMDbv Tech SA Ads (NASDAQ:DBVT) Shorted Shares Increased By 5.19% - Consumer Eagle
07/12/16 08:56 PMAre Analysts Bearish DBV Technologies SA - ADR (NASDAQ:DBVT) After Last Week? - Consumer Eagle
07/12/16 03:53 AMHalf year update on the DBV Technologies liquidity agreement - [at noodls] - 4b85791b-d450-4900-8299-2e9b48c7af90.pdf Press Release Montrouge, France, July 11th, 2016 Half year update on the DBV Technologies liquidity agreement Montrouge, France, July 11th - As per the liquidity ...
07/08/16 03:34 PMIs $64 Within Reach For DBV Technologies S.A. (NASDAQ:DBVT)? - Investor Newswire
07/05/16 08:16 AMDBV Technologies S.A. (NASDAQ:DBVT) Updated Price Targets - FTSE News
07/05/16 12:34 AMDBV Technologies Proudly Welcomes Dr. Lucia Septien as Chief Medical Officer - [GlobeNewswire] - MONTROUGE, France -- DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage specialty biopharmaceutical company, today announced the appointment of Lucia Septien, ...
07/04/16 03:19 PMThis Weeks Broker Price Targets For DBV Technologies S.A. (NASDAQ:DBVT) - Fiscal Standard
07/01/16 08:40 PMDBV Technologies S.A. (NASDAQ:DBVT) Expected to Reach Highs Of $64 - Investor Newswire
06/30/16 08:52 AMDbv Tech SA Ads (NASDAQ:DBVT) Sellers Increased By 5.19% Their Shorts - Engelwood Daily
06/29/16 08:35 PMWhat's Next for DBV Technologies SA - ADR After Today's Huge Increase? - Engelwood Daily
06/27/16 03:41 PMDBV Technologies Announces Completion of Recruitment in Global Phase III Study of Viaskin Peanut for the Treatment of Peanut Allergic Children - [at noodls] - 33131379-e6fe-42e2-9f48-845ca6ea17ef.pdf Press Release Montrouge, France, June 27, 2016 DBV Technologies Announces Completion of Recruitment in Global Phase III Study of Viaskin Peanut for the Treatment ...
06/21/16 03:39 PMDBV Technologies Expands its Board of Directors with the Appointments of Claire Giraut and Maïlys Ferrere - [at noodls] - 1003aa0c-cf5a-462d-b1eb-434a5826f82b.pdf Press Release Montrouge, France, June 21, 2016 DBV Technologies Expands its Board of Directors with the Appointments of Claire Giraut and Maïlys Ferrere DBV Technologies ...
06/21/16 03:39 PMDBV Announced Results of its 2016 Annual Meeting of Shareholders - [at noodls] - 7c68e2bb-6bc1-4354-adce-6bc5c46dbb0e.pdf Regulated Information Montrouge, France, June 21, 2016 DBV Announced Results of its 2016 Annual Meeting of Shareholders Adoption of all resolutions submitted to ...
06/21/16 03:36 PMDBV Technologies Announced Results of its 2016 Annual Meeting of Shareholders - [GlobeNewswire] - Montrouge, France -- DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage specialty biopharmaceutical company, held today its Combined Shareholders' Meeting, ...
06/21/16 03:32 PMDBV Technologies Expands its Board of Directors with the Appointments of Claire Giraut and Mailys Ferrere - [GlobeNewswire] - Montrouge, France -- DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage specialty biopharmaceutical company, today announced the appointment of Claire Giraut ...
06/17/16 08:11 AMAdobe Systems (ADBE): A Surprise in Q2 Earnings Release? -
06/16/16 03:49 PMDBV Technologies to Present at the JMP Securities Life Sciences Conference - [at noodls] - e12292e5-73d9-4d07-b8a9-a8d387c5395c.pdf Press Release Montrouge, France, June 16, 2016 DBV Technologies to Present at the JMP Securities Life Sciences Conference DBV Technologies, (Euronext: DBV - ISIN: ...
06/15/16 03:39 PMLate-Breaking Presentation at EAACI Highlights Viaskin® Peanut Data Providing Biomarker Insights for Monitoring Treatment Progression - [at noodls] - 1de329d1-d483-4fe0-b493-29c5bb5a77c7.pdf Press Release Vienna, Austria, June 15, 2016 Late-Breaking Presentation at EAACI Highlights Viaskin® Peanut Data Providing Biomarker Insights for Monitoring Treatment ...
06/15/16 03:34 PMDBV Technologies: Late-Breaking Presentation at EAACI Highlights Viaskin(r) Peanut Data Providing Biomarker Insights for Monitoring Treatment Progression - [GlobeNewswire] - Early-Stage Proprietary Model Suggests that Serum Biomarkers may help Monitor Treatment Progression with Viaskin Peanut
06/07/16 03:38 PMDBV Technologies Announces Appointment of Leading Japanese Allergist, Dr. Motohiro Ebisawa, to its Scientific Advisory Board - [at noodls] - 91a2f551-8c7b-4bf3-af1f-625018261527.pdf Press Release Montrouge, France, June 7, 2016 DBV Technologies Announces Appointment of Leading Japanese Allergist, Dr. Motohiro Ebisawa, to its Scientific Advisory ...
06/07/16 03:11 PMDBV Technologies Forms 'Magic' Partnership With Nestle -
06/01/16 12:38 AMDBV Technologies Data at EAACI 2016 Highlight Its Expansive Product Development in Food Allergies - [GlobeNewswire] - Nine Presentations Continue to Support the Potential Use of the Viaskin(R) Technology in Food Allergies
05/31/16 12:51 PMNestle Partnership Gives DBV Investors a Treat -
05/31/16 08:02 AMDBV Technologies and Nestlé Health Science Form Collaboration to Develop and Commercialize a Novel Diagnostic Test for Pediatric Milk Allergy - [at noodls] - d95d8d73-2fec-45f9-864b-d781e4f02da8.pdf Press Release Montrouge, France, May 31, 2016 DBV Technologies and Nestlé Health Science Form Collaboration to Develop and Commercialize a Novel Diagnostic Test ...
05/31/16 08:02 AMJune 21, 2016 General Assembly - [at noodls] - 6355edcf-be0c-41f1-b79e-7544bf8cad7a.pdf DBV TECHNOLOGIES 177-181 AVENUE PIERRE-BROSSOLETTE 92120 MONTROUGE AU CAPITAL DE EUR 2 431 345,30 441 772 522 RCS NANTERRE ASSEMBLEE GENERALE MIXTE DU 21 JUIN 2016 ...
05/31/16 12:06 AMDBV Technologies and Nestle Health Science Form Collaboration to Develop and Commercialize a Novel Diagnostic Test for Pediatric Milk Allergy - [GlobeNewswire] - BAGNEUX, France --
05/30/16 06:26 PMDbv Tech SA Ads (NASDAQ:DBVT) Shorted Shares Decreased By 11.89% - HNN - Dbv Tech SA Ads (NASDAQ:DBVT) Shorted Shares Decreased By 11.89%HNNThe stock of Dbv Tech SA Ads (NASDAQ:DBVT) registered a decrease of 11.89% in short interest. DBVT's total short interest was 377,900 shares in May as published by FINRA. Its down 11.89% from 428,900 shares, reported previously. With 156,600 shares ...
05/30/16 06:26 PMStrong Sell Calls Count For DBV Technologies S.A. (NASDAQ:DBVT) At 0 - Investor Newswire - Strong Sell Calls Count For DBV Technologies S.A. (NASDAQ:DBVT) At 0Investor NewswireDBV Technologies S.A. (NASDAQ:DBVT) has a total of 5 Strong Buy calls and 0 Strong Sell advises as of 2016-05-29. Zacks uses a rating procedure which assigns scores to stocks on a narrow 1-5 scale. When a stock gets a score of 1 or 2, it is considered ...and more »
05/30/16 03:46 PMDBV Technologies: Mixed General Assembly of June 21, 2016 Procedures for obtaining preparatory documents for the Assembly - [GlobeNewswire] - MONTROUGE, France -- DBV Technologies, (Euronext: DBV - ISIN: FR0010417345 - NASDAQ: DBVT), a clinical-stage specialty biopharmaceutical company, announces that it will hold its Mixed General Assembly ...
05/30/16 03:40 PMMixed General Assembly of June 21, 2016 Procedures for obtaining preparatory documents for the Assembly - [at noodls] - d2180379-c522-4698-a4d3-73ce8382f3ca.pdf Regulated Information Montrouge, France, May 30, 2016 Mixed General Assembly of June 21, 2016 Procedures for obtaining preparatory documents for the Assembly DBV ...
05/20/16 02:33 AMDBV Technologies to Attend Upcoming Investor Conferences - [at noodls] - d7e2ea5b-ff70-4fbe-a854-0decd25899be.pdf Press Release Montrouge, France, May 20, 2016 DBV Technologies to Attend Upcoming Investor Conferences DBV Technologies, (Euronext: DBV - ISIN: FR0010417345 - Nasdaq ...
04/29/16 12:54 AMDBV Technologies Reports March 31, 2016 Cash Position - [at noodls] - 71c28dfa-2717-4a77-a8eb-dcccefa1dc24.pdf Press Release Montrouge, France, April 29, 2016 DBV Technologies Reports March 31, 2016 Cash Position DBV Technologies, (Euronext: DBV - ISIN: FR0010417345 - Nasdaq ...
04/28/16 04:41 PM20-F Form - [at noodls] - printmgr file UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 ...
04/28/16 04:41 PMDBV Technologies Announces Filing of 2015 “Document de Référence” and 2015 Annual Report on Form 20-F - [at noodls] - 3a644b37-65d4-41e8-8953-8f0e250b8fec.pdf Press Release Montrouge, France, April 28, 2016 DBV Technologies Announces Filing of 2015 "Document de Référence" and 2015 Annual Report on Form 20-F ...
04/28/16 04:34 PMDBV Technologies Announces Filing of 2015 "Document de Reference" and 2015 Annual Report on Form 20-F - [GlobeNewswire] - MONTROUGE, France -- DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage specialty biopharmaceutical company, today announced the filing of its 2015 Annual ...
04/11/16 03:41 PMDBV Technologies Announces Publication of Experimental Data on Targeted Regulatory T Cell Induction during Epicutaneous Immunotherapy - [at noodls] - cf9d795c-eaad-4526-b299-be43d8fa820c.pdf Press Release Montrouge, France, April 11, 2016 DBV Technologies Announces Publication of Experimental Data on Targeted Regulatory T Cell Induction during Epicutaneous ...
02/26/16 12:35 PMDbv Tech SA Ads (NASDAQ:DBVT) Shorted Shares Increased By 10.3% - Clinton Financial - Dbv Tech SA Ads (NASDAQ:DBVT) Shorted Shares Increased By 10.3%Clinton FinancialThe stock of Dbv Tech SA Ads (NASDAQ:DBVT) registered an increase of 10.3% in short interest. DBVT's total short interest was 511,700 shares in February as published by FINRA. Its up 10.3% from 463,900 shares, reported previously. With 159,400 shares ...
02/26/16 12:35 PMCreating Profits For Investors: DBV Technologies S.A.( NASDAQ:DBVT ) - Franklin Independent - Creating Profits For Investors: DBV Technologies S.A.( NASDAQ:DBVT )Franklin IndependentShares of DBV Technologies S.A. (NASDAQ:DBVT) are showing a bullish trend as the stock has given investors a 10.91% increase over the past 5 trading days. Given the recent market volatility, both institutions and retail stakeholders might be ...
02/26/16 12:35 PMWere Analysts Bearish DBV Technologies SA - ADR (NASDAQ:DBVT) This Week? - Franklin Independent - Were Analysts Bearish DBV Technologies SA - ADR (NASDAQ:DBVT) This Week?Franklin IndependentOut of 7 analysts covering DBV Technologies (NASDAQ:DBVT), 7 rate it “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. $62.01 is the highest target while $47.01 is the lowest. The $52.72 average target is 105.55% above today's ($25.6 ...
02/25/16 04:08 PM5:08 pm DBV Technologies announces the publication of results from a Phase Ib trial showing that Viaskin Peanut was observed to have a favorable safety and tolerability profile -
02/25/16 03:56 PMDBV Technologies Announces Publication of Phase Ib Trial Results in the Journal of Allergy and Clinical Immunology (JACI) Supporting Safety and Tolerability of Viaskin(R) Peanut - [GlobeNewswire] - MONTROUGE, France -- DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage specialty biopharmaceutical company, today announced the publication of results ...
02/15/16 12:34 AMDBV Technologies Reports December 31, 2015, Cash Position - [GlobeNewswire] - MONTROUGE, France -- DBV Technologies, (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage specialty biopharmaceutical company, today announced its cash and cash equivalents ...
02/14/16 01:57 PMDbv Tech SA Ads (NASDAQ:DBVT) Short Interest Increased By 10.3% - fdanewsalert.com - Dbv Tech SA Ads (NASDAQ:DBVT) Short Interest Increased By 10.3%fdanewsalert.comThe stock of Dbv Tech SA Ads (NASDAQ:DBVT) registered an increase of 10.3% in short interest. DBVT's total short interest was 511,700 shares in February as published by FINRA. Its up 10.3% from 463,900 shares, reported previously. With 159,400 shares ...
02/10/16 08:01 AMDBV Technologies to Present New Data at the 2016 AAAAI Annual Meeting - [GlobeNewswire] - 2-Year Follow-Up of Clinical Data Further Support Viaskin(R) Peanut's Efficacy and Safety Profile
01/26/16 01:37 AMDBV Technologies Proudly Welcomes Edward Jordan as Senior Vice President Commercial Operations North America - [at noodls] - 79cfe6de-ac03-43eb-8f59-fa07fc78752f.pdf Press Release Montrouge, France, 26 January, 2016 DBV Technologies Proudly Welcomes Edward Jordan as Senior Vice President Commercial Operations North America DBV ...
11/12/15 04:19 PMDBV Technologies Announces Enrollment of First Patient in Phase IIA Study in Pediatric Eosinophilic Esophagitis - [GlobeNewswire] - BAGNEUX, France -- DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage specialty biopharmaceutical company, today announced that the first patient has been ...

Social

About DBV Technologies SA -

DBV Technologies SA - logoDBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. It dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The Company's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The Company operates one subsidiary DBV Technologies Inc. in the United States.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Diagnostic Substances
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: DBVT
  • CUSIP:
Key Metrics:
  • Previous Close: $34.60
  • 50 Day Moving Average: $32.38
  • 200 Day Moving Average: $30.64
  • P/E Ratio: N/A
  • P/E Growth: -0.43
  • Market Cap: $1.59B
  • Beta: 1.52
  • Current Year EPS Consensus Estimate: $-2.59 EPS
  • Next Year EPS Consensus Estimate: $-3.22 EPS
Additional Links:
DBV Technologies SA - (NASDAQ:DBVT) Chart for Saturday, July, 30, 2016